Dr. Reddy's Laboratories Limited (DRREDDY) — Financial Results | 31 May 2025

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Dr. Reddy's Laboratories reported consolidated net profit of ₹67.82 crores for Q4 FY2025, up 32% YoY from ₹51.35 crores in Q4 FY2024, driven by strong revenue growth to ₹2,246.69 crores (+10% YoY). The company posted robust earnings per share of ₹2.67 post-exceptional items, reflecting improved operational performance and margin expansion.

📄 View Original Announcement (PDF)

About Dr. Reddy's Laboratories Limited (DRREDDY)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,11,568.6 Cr P/E: 20.0 ROE: 16.6% ROCE: 19.7%

View full DRREDDY stock details →

📡 Get AI alerts when DRREDDY files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DRREDDY — Free

📊 More DRREDDY filings

See all DRREDDY filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DRREDDY files new disclosures

Track DRREDDY filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track DRREDDY — Free

Free account · 2 AI queries/day